Department of Clinical Pharmacology, Faculty of Medicine, Suez Canal University, Egypt.
Department of Clinical Pharmacology, Faculty of Medicine, Suez Canal University, Egypt.
Pharmacol Rep. 2018 Jun;70(3):509-518. doi: 10.1016/j.pharep.2017.11.017. Epub 2017 Nov 28.
In liver fibrosis, a major morbid and mortal disease, oxidative stress motivation of hepatic stellate cells (HSCs)-into myofibroblasts terminated in collagen deposition remain the key pathophysiological deal. Serotonin (5-HT) through its HSCs-expressed receptors, especially 5-HT2A and 7, shows crucial events in fibrogenesis of chronic liver diseases. Molecular hepatic oxidative stress-fibrotic roles of 5-HT2A and 7 receptors antagonists (ketanserin and SB-269970 respectively) are still a challenging issue.
Seven groups of adult male Wistar rats (n=10) were used. A carbon tetrachloride (CCl) solution was injected intraperitoneally twice weekly for 6 weeks. On the 7th week, rats developed liver fibrosis were treated either by ketanserin (1mg/kg/day, ip) or SB-269970 (2mg/kg/day, ip) for 14days. Survival rates, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in addition to hepatic malondialdehyde (MDA) and reduced glutathione (GSH) levels, superoxide dismutase (SOD) and catalase (CAT) activities, and transforming growth factor-beta1 (TGF-β) and procollagen type I N-terminal propeptide (PINP) levels, beside the hepatic histopathological fibrotic changes, were evaluated.
In CCl-challenged rats, each therapeutic approach showed significant reductions in elevated serum ALT, and AST levels, hepatic MDA, TGF-β, and PINP levels, and histopathological hepatic fibrotic scores as well as significant elevations in survival rates, reduced hepatic GSH levels, and SOD, and CAT activities. Remarkably, significant ameliorative measurements were observed in SB-269970 treated group.
Blockade of 5-HT2A and 7 receptors each alone could be a future reliable therapeutic approach in liver fibrosis through a reduction in oxidative stress/TGF-β-induced HSCs activation pathway.
在肝纤维化这一主要的致死致残疾病中,肝星状细胞(HSCs)向肌成纤维细胞转化的氧化应激驱动作用导致胶原沉积,这仍然是关键的病理生理过程。血清素(5-HT)通过其在 HSCs 上表达的受体,尤其是 5-HT2A 和 7,在慢性肝病的纤维化形成中显示出关键事件。5-HT2A 和 7 受体拮抗剂(酮康唑和 SB-269970)的分子肝氧化应激-纤维化作用仍然是一个具有挑战性的问题。
使用 7 组成年雄性 Wistar 大鼠(n=10)。每周两次腹膜内注射四氯化碳(CCl)溶液,共 6 周。在第 7 周,大鼠发生肝纤维化,用酮康唑(1mg/kg/天,ip)或 SB-269970(2mg/kg/天,ip)治疗 14 天。评估生存率、血清丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)水平,以及肝丙二醛(MDA)和还原型谷胱甘肽(GSH)水平、超氧化物歧化酶(SOD)和过氧化氢酶(CAT)活性、转化生长因子-β1(TGF-β)和前胶原 I 型 N 端前肽(PINP)水平,以及肝组织病理学纤维化变化。
在 CCl 挑战的大鼠中,每种治疗方法都显著降低了升高的血清 ALT 和 AST 水平、肝 MDA、TGF-β和 PINP 水平以及组织病理学肝纤维化评分,同时显著提高了生存率、降低了肝 GSH 水平、SOD 和 CAT 活性。值得注意的是,在 SB-269970 治疗组观察到了更显著的改善措施。
单独阻断 5-HT2A 和 7 受体可能是肝纤维化的一种有前途的治疗方法,通过减少氧化应激/TGF-β诱导的 HSCs 激活途径。